OECD Home › Chemical safety and biosafety › Testing of chemicals › Latest Documents
This guidance document proposes an integrated approach on testing and assessment for skin corrosion and irritation, in view of replacing the "testing and evaluation strategy" provided in the supplement to OECD TG404 (to be updated), provides information on key performance characteristics of each information source comprising the IATA, and guidance on how to integrate information for decision making for classification and labeling.
This is the OECD Good Laboratory Practice homepage. The primary objective of the OECD Principles of GLP is to ensure the generation of high quality and reliable test data related to the safety of industrial chemical substances.
This section addresses questions and answers regarding the OECD Test Guidelines Programme (TGP).
An IT system to develop and evaluate Adverse Outcome Pathways (AOP), the AOP Wiki, has been developed for testing by the Extended Advisory Group on Molecular Screening and Toxicogenomics and by AOP developers included in the work plan. The Wiki provides developers the necessary steps to capture scientific information in a user-friendly manner. The project is jointly led by the ECJRC and the USEPA.
Presentation by Endpoints: Section 2 - Effects on Biotic Systems
On 26 July 2013, the OECD Council adopted three new, six updated and one corrected OECD Test Guidelines for the testing of chemicals, as well as a new Introduction to the Section 5, Part A on Pesticides Residue Chemistry.
This biocide document provides guidance on the conduct of laboratory and field tests aimed to assess the efficacy of anti-ants baits for indoor use. A bait contains one or more insecticidal active ingredients combined with food for garden ants.
OECD Work Related to Endocrine Disrupters
This document describes four quantitative methods for efficacy evaluation: bactericidal, mycobactericidal, fungicidal and virucidal. Regulatory authorities have relied upon efficacy data generated using these methods to authorise the placing of biocidal products on the market.
The objective of the Guidance Document is to provide guidance on how to interpret the outcome of individual tests and how to increase evidence on whether or not a substance may be an endocrine disrupter. However, testing strategies or guidance on interpretation from a suite of tests are not given.